Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Dow
McKinsey
Harvard Business School
Medtronic

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Glembatumumab vedotin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Glembatumumab vedotin?

Glembatumumab vedotin is an investigational drug.

There have been 7 clinical trials for Glembatumumab vedotin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Melanoma, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Celldex Therapeutics, National Cancer Institute (NCI), and University of Virginia.

There are six US patents protecting this investigational drug and forty-nine international patents.

Recent Clinical Trials for Glembatumumab vedotin
TitleSponsorPhase
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1/Phase 2
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerCelldex TherapeuticsEarly Phase 1
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerUniversity of VirginiaEarly Phase 1

See all Glembatumumab vedotin clinical trials

Clinical Trial Summary for Glembatumumab vedotin

Top disease conditions for Glembatumumab vedotin
Top clinical trial sponsors for Glembatumumab vedotin

See all Glembatumumab vedotin clinical trials

US Patents for Glembatumumab vedotin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Glembatumumab vedotin   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Glembatumumab vedotin   Start Trial Compositions and methods for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
Glembatumumab vedotin   Start Trial P97 fragments with transfer activity biOasis Technologies, Inc. (Vancouver, British Columbia, unknown)   Start Trial
Glembatumumab vedotin   Start Trial Fragments of p97 and uses thereof biOasis Technologies, Inc. (Richmond, CA)   Start Trial
Glembatumumab vedotin   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Glembatumumab vedotin

Drugname Country Document Number Estimated Expiration Related US Patent
Glembatumumab vedotin Australia 2013220749 2032-02-15   Start Trial
Glembatumumab vedotin Brazil 112014019627 2032-02-15   Start Trial
Glembatumumab vedotin Canada 2862476 2032-02-15   Start Trial
Glembatumumab vedotin China 104114705 2032-02-15   Start Trial
Glembatumumab vedotin China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
Colorcon
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.